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Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are
urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the
memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and
identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites
on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of
somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory
B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV,
SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing
S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal
a target for the rational design of pan-sarbecovirus vaccines.
I
nDecember 2019, a novel pathogen emerged
in the city of Wuhan in China’s Hubei
province, causing an outbreak of atypical
pneumonia [a disease known as corona-
virus disease 2019 (COVID-19)]. The in-
fectious agent was characterized as a lineage
B betacoronavirus, named severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) and
shown to be closely related to SARS-CoV and
several SARS-like bat CoVs (1). There are cur-
rently no approved vaccines or therapeutics avail-
able for thepreventionor treatment ofCOVID-19.
CoV entry into host cells is mediated by the
viral S glycoprotein, which forms trimeric
spikes on the viral surface (2). Eachmonomer
in the trimeric S assembly is a heterodimer
of S1 and S2 subunits. The S1 subunit is
composed of four domains: an N-terminal
domain (NTD), a C-terminal domain (CTD),
and subdomains I and II (3–5). The CTD of
both SARS-CoV and SARS-CoV-2 functions as
the receptor-binding domain (RBD) for the
shared entry receptor, human angiotensin-
converting enzyme 2 (hACE2) (6–10). The S2
subunit contains the fusion peptide, heptad
repeats 1 and 2, and a transmembrane do-
main, all of which are required for fusion of
the viral and host cell membranes.
The S glycoprotein of HCoVs is the primary
target for neutralizing antibodies (nAbs) (11).
SARS-CoV and SARS-CoV-2 share 76% amino
acid identity in their S proteins, raising the
possibility of conserved immunogenic surfaces
on these antigens. Studies of convalescent sera
and a limited number of monoclonal anti-
bodies (mAbs) have revealed limited to no
cross-neutralizing activity, demonstrating that
conserved antigenic sites are rarely targeted
by nAbs (5, 9, 12, 13). However, the frequencies,
specificities, and functional activities of cross-
reactive antibodies induced by natural SARS-
CoV and SARS-CoV-2 infection remain poorly
defined.
We aimed to comprehensively profile the
cross-reactive B cell response induced by SARS-
CoV infection by cloning an extensive panel
of SARS-CoV-2 S-reactive mAbs from the pe-
ripheral B cells of a convalescent donor (do-
nor 84) who survived the 2003 SARS outbreak.
To isolate cross-reactive antibodies, we ob-
tained a blood sample from this donor about
3 years after infection and stained purified
B cells with a panel of memory B cell (MBC)
markers and a fluorescently labeled SARS-
CoV-2 S protein. Flow cytometric analysis
revealed that 0.14% of class-switched MBCs
were SARS-CoV-2 S-reactive, which was about
threefold greater than background staining ob-
served with a SARS-CoV–naïve donor sample
(Fig. 1A). Cognate antibodyheavy- and light-chain
pairs were amplified from 315 individual SARS-
CoV-2–reactive B cells by single-cell reverse tran-
scription polymerase chain reaction (RT-PCR)
and subsequently cloned and expressed as full-
length immunoglobulin Gs (IgGs) in an engi-
neered strain of Saccharomyces cerevisiae (14).
Of the 315 cloned antibodies, 200 bound to
SARS-CoV-2 S in preliminary binding screens
(Fig. 1B). Sequence analysis revealed that
about half of the clones were members of
expanded clonal lineages, whereas the other
half were unique (Fig. 1C). Moreover, about
30% of isolated antibodies displayed convergent
VH1-69/VK2-30 germline gene pairing (Fig. 1C).
As expected, almost all the antibodies were
somatically mutated, with members of clo-
nally expanded lineages showing significantly
higher levels of somatic hypermutation (SHM)
compared with unique clones (Fig. 1D). Finally,
consistent with the respiratory nature of SARS-
CoV infection, index sorting analysis revealed
that 33% of binding antibodies originated from
IgA+ MBCs and the remaining 66% from IgG+
MBCs (Fig. 1E). We conclude that SARS-CoV
infection elicited a high frequency of long-lived,
cross-reactive MBCs in this donor.
We next measured the apparent binding af-
finities (KD
Apps) of the antibodies to prefusion-
stabilized SARS-CoV and SARS-CoV-2 S proteins
(5). Althoughmost antibodies (153 out of 200)
showed binding to both S proteins, a subset
appeared to be SARS-CoV-2 S-specific (Fig. 2A).
This result was unexpected given that the
antibodies were isolated from a SARS-CoV–
experienced donor and may relate to differ-
ences between the infecting SARS-CoV strain
and the recombinant SARS-CoVSprotein (Tor2)
used for the binding studies. Alternatively, this
result may be due to inherent differences in
the stability or antigenicity of recombinant
prefusion-stabilized SARS-CoV and SARS-CoV-2
S proteins. Indeed, about 30% of antibodies
that failed to bind recombinant SARS-CoV S
displayed reactivity with SARS-CoV S expressed
on the surface of transfected cells, providing
some evidence for differences in the anti-
genicity of recombinant and cell-expressed
forms of S (fig. S1).
Paradoxically, most of the highly mutated
and clonally expanded antibodies boundweakly
(KD
Apps > 10 nM) to both SARS-CoV and SARS-
CoV-2 S (Fig. 2B). We sought to determine if
these antibodies originated from preexisting
MBCs induced by prior exposures to naturally
circulating HCoVs, which share up to 32%
S amino acid identity with SARS-CoV and
SARS-CoV-2. Accordingly, we assessed bind-
ing of the antibodies to recombinant S proteins
of naturally circulating human alphacoronavi-
ruses (HCoV-NL63 and HCoV-229E) and beta-
coronaviruses (HCoV-OC43 and HCoV-HKU1).
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More than 80% of the low-affinity (KD
Apps >
10 nM) SARS-CoV and SARS-CoV-2 cross-
reactive antibodies reacted with one or more
of the HCoV S proteins, suggesting that SARS-
CoV infection may have boosted a preexisting
MBC response induced by circulating HCoVs
(Fig. 2B). Consistent with this hypothesis, the
broadly cross-reactive antibodies showed sig-
nificantly higher levels of SHM and clonal
expansion compared with those that only
recognized SARS-CoV and SARS-CoV-2 (Fig.
2, B to D). Furthermore, 72% of the broadly
binding antibodies used VH1-69/VK2-30 germ-
line gene pairing, suggesting germline-mediated
recognition of a common antigenic site (Fig. 2B
and fig. S2). Although we were unable to finely
map the epitopes recognized by these anti-
bodies, none of them bound to recombinant
SARS-CoV-2 S1, suggesting that they likely
target epitopes within the more conserved S2
subunit (fig. S3). Index sorting analysis re-
vealed that the majority of the broadly cross-
reactive antibodies were derived from IgA+
MBCs, indicating a mucosal origin, whereas
most of the SARS-CoV and SARS-CoV-2 cross-
reactive antibodies originated from IgG+MBCs
(Fig. 2E). Finally, all of the broad binders
lacked polyreactivity, demonstrating that
their cross-binding is not due to nonspecific
cross-reactivity (fig. S4).
To investigate whether the above results
were due to an original antigenic sin phenom-
enon, or rather simply due to avid binding
of circulating HCoV-specific B cell receptors
to the SARS-CoV-2 S tetramers used for cell
sorting, we assessed whether similarly broadly
binding antibodies were also present in SARS-
CoV– and SARS-CoV-2–naïve donors that had
been exposed to endemicHCoVs.We obtained
peripheral blood mononuclear cell (PBMC)
samples from three healthy adult donors with
serological evidence of circulating HCoV expo-
sure and no history of SARS-CoV or SARS-
CoV-2 infection and stained the corresponding
B cells with a fluorescently labeled SARS-
CoV-2 S probe (fig. S5A). Flow cytometric
analysis revealed that between 0.06 and
0.12% of total B cells in the three naïve donors
displayed SARS-CoV-2 reactivity (fig. S5B).
More than 350 SARS-CoV-2–reactive MBCs
were sorted and amplified by single-cell RT-
PCR, and 141 variable region of Ig heavy chain
(VH)–variable region of Ig light chain (VL) pairs
were cloned and expressed as full-length IgGs.
Although a limited number of SARS-CoV-2 S
binding antibodies (3 to 22) were isolated from
all three naïve donors, they displayed signif-
icantly lower levels of SHM, clonal expansion,
and KD
Apps for both SARS-CoV and SARS-
CoV-2 S compared with the cross-reactive
antibodies identified from donor 84 (Fig. 2, F
and G, and fig. S5C). Altogether, these results
suggest that SARS-CoV infection likely led to
the activation and expansion of preexisting
cross-reactive MBCs induced by circulating
HCoV exposure in this donor.
To map the antigenic sites recognized by
the SARS-CoV and SARS-CoV-2 cross-reactive
antibodies isolated from donor 84, we per-
formed binding experiments using a panel of
recombinant S protein subunits and individ-
ual domains. Because of the inherent technical
challenges associated with measuring binding
of low-affinity antibodies to monomeric pro-
teins, we analyzed only the 64 high-affinity
binders (KD
Apps < 10 nM) to SARS-CoV-2 S
(Fig. 2, A and B). We first evaluated binding
to recombinant SARS-CoV-2 S1 and S2 sub-
units and observed that 75% of the antibodies
recognized epitopes within S1, whereas the
remaining 25% bound to epitopes within S2
(Fig. 3A). Two of the S2-directed antibodies
also showed strong reactivity with OC43 S,
suggesting recognition of a conserved anti-
genic site (fig. S6). We next evaluated the
49 S1-directed antibodies for reactivity with
individual SARS-CoV-2 RBD and NTD pro-
teins and found that 21 (43%) and 28 (57%) of
the S1-specific antibodies recognized the RBD
and NTD, respectively (Fig. 3A).
To further define the epitopes recognized
by the 21 RBD-directed antibodies, we per-
formed competitive binding studies with re-
combinant hACE2 and a previously described
antibody, CR3022, that targets a conserved
epitope that is distinct from the receptor
binding site (Fig. 3B and fig. S7) (15). Six of
the antibodies competed only with hACE2,
three competed only with CR3022, four com-
petedwith both hACE2 andCR3022, and seven
did not compete with hACE2 or CR3022 (Fig.
3B). Thus, these antibodies delineate at least
four adjacent and potentially overlapping sites
within the RBD. Most of the antibodies that
competed with recombinant hACE2 binding to
SARS-CoV-2 RBD in the biolayer interferome-
try (BLI) assay also interfered with binding of
full-length SARS-CoV-2 S to endogenous ACE2
expressed on the surface of Vero E6 cells
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Fig. 1. Isolation of SARS-CoV-2 S-specific antibodies. (A) Frequency of SARS-CoV-2 S-reactive B cells
in donor 84 and a SARS-CoV–naïve donor. Fluorescence-activated cell sorting plots are gated on
CD19+CD20+IgD−IgM− B cells. swIg, switched immunoglobulin. (B) Binding of 315 isolated antibodies to
SARS-CoV-2 S, as determined by BLI. The dashed line indicates the threshold for designating binders
(0.1 nm). (C) Clonal lineage analysis. Each lineage is represented as a segment proportional to the lineage
size. The total number of antibodies is shown in the center of the pie. Clonal lineages were defined based on
the following criteria: identical VH and VL germline genes, identical CDR H3 (third complementarity-
determining region of the heavy chain) length, and CDR H3 amino acid identity ≥80%. (D) Somatic
mutation load, expressed as the number of nucleotide substitutions in VH, in unique antibodies and members
of expanded clonal lineages. Red bars indicate medians. Statistical comparisons were made using the
Mann-Whitney test (****P < 0.0001). (E) Proportion of SARS-CoV-2 S binders derived from IgG+ and IgA+
B cells, as determined by index sorting.
formedneutralization assays using bothmurine
leukemia virus (MLV)– and vesicular stomatitis
virus (VSV)–based pseudotype systems as well
as authentic SARS-CoV-2. Because of the large
number of antibodies, we first measured infec-
tion inhibition of authentic SARS-CoV-2 at a
single concentration of purified IgG. Only 9
out of 200 antibodies displayed neutralizing
activity at the 100 nM concentration tested,
eight targeted the RBD, and the remaining
one recognized the NTD (Fig. 3D). Similar
results were observed in the VSV-based pseu-
dovirus assay (fig. S8). Of the eight RBD-
directed nAbs, four targeted epitopes overlapping
with both the hACE2 and CR3022 epitopes
and the other four recognized epitopes over-
lapping only the hACE2 epitope, suggesting
the existence of two partially overlapping neu-
tralizing epitopes within the RBD (Fig. 3B).
Neutralization titration studies revealed that
the median inhibitory concentrations (IC50s)
of the RBD-directed nAbs ranged from 0.05








S proteins, as determined by
BLI. Low-affinity clones for
which binding curves could not
be fit are designated as “poor
fit” (p.f.) on the plot. n.b.,
nonbinder. (B) IgG KD
Apps for
SARS-CoV-2, SARS-CoV, 229E,
HKU1, NL63, and OC43 S
proteins. Germline gene usage,
clonality, and SHM are
presented in the three left-
most columns. SHM load
is represented as the number
of nucleotide substitutions
in VH. (C) Load of somatic
mutations in broadly cross-
reactive and SARS-CoV–
and SARS-CoV-2–specific
antibodies. Red bars indicate
medians. (D) Degree of clonal




is represented as a segment
proportional to the lineage
size. The total number of anti-
bodies is shown in the center




from IgG+ and IgA+ B cells, as
determined by index sorting.
(F) Load of somatic mutations
in SARS-CoV-2 S-reactive
antibodies isolated from three
naïve donors and donor 84.
Antibodies from healthy
donors were combined for this
analysis. (G) Binding activity
of antibodies isolated from
SARS-CoV-2 S-reactive B cells in donor 84 and three naïve donors to SARS-CoV and SARS-CoV-2 S proteins, as determined by BLI. Statistical comparisons

























































































































































































































ADI-55993, ADI-56000, and ADI-56035) that 
showed stronger competition in the BLI assay 
displayed weak binding affinities for SARS-
CoV-2 S (fig. S12), which likely explains their 
lower level of competition in the cell-surface 
assay. Thus, SARS-CoV infection elicited high-
affinity cross-reactive antibodies to a range 
of antigenic sites within both the S1 and S2 
subunits.
To evaluate the neutralization activities of 





















































































































































































































































































































































































































Fig. 3. Epitope mapping and neutralization screening. (A) Proportion of SARS-
CoV-2 S-specific antibodies targeting each of the indicated antigenic sites.
(B) Heat map showing the competitive binding profiles of the RBD-directed
antibodies, as determined by BLI (top) and percent neutralization of authentic
SARS-CoV-2 at a 100 nM concentration (bottom). (C) Antibody inhibition of
SARS-CoV-2 S binding to endogenous ACE2 expressed on Vero E6 cells, as
determined by flow cytometry. Antibodies were mixed with recombinant SARS-CoV-2
S bearing a Twin-Strep tag at a molar ratio of 10:1 before adding to Vero E6 cells.
An anti-ebolavirus antibody (KZ52) was used as an isotype control. The “no
antigen” control indicates secondary-only staining. The asterisk indicates that no
detectable binding was observed. Bars are colored according to epitope specificity,
as determined in the BLI competition assay. Data represent three technical
replicates. (D) Percent authentic SARS-CoV-2 neutralization in the presence of
100 nM IgG. Antibodies are grouped according to epitope specificity. RBD-directed
antibodies that compete or do not compete with ACE2 are designated as ACE2 and
non-ACE2, respectively. (E) Antibody neutralization of SARS-CoV and SARS-CoV-2
MLV pseudovirus (strain n-CoV/USA_WA1/2020) using HeLa-ACE2 target cells, and
neutralization of authentic SARS-CoV, SARS-CoV-2, and WIV1-CoV using Vero E6
target cells. Data represent two technical replicates. (F) Binding EC50s for
cell-surface SARS-CoV-2 S are plotted against the percent neutralization
of authentic SARS-CoV-2 at 100 nM. Background binding was assessed using
mock-transfected HEK-293 cells. Data points are colored according to epitope
specificity. RBD-directed antibodies are further categorized based on their
competition group: hACE2 indicates hACE2-only competitors; CR3022 indicates
CR3022-only competitors; hACE2/CR3022 indicates antibodies that compete
with hACE2 and CR3022; other indicates hACE2 and CR3022 noncompetitors.
Antibodies with cell binding EC50s >100 nM are designated as weak binders (w.b.) on
the plot. (G) Antibody binding activity to cell-surface SARS-CoV-2 S over time,
as determined by flow cytometry. IgGs were incubated with cells expressing WT
SARS-CoV-2 over the indicated time intervals. Binding MFI was assessed at
240 min for all samples. CR3022 is included for comparison. Curves are colored by
epitope specificity, as in (F). Data represent two technical replicates.
to 1.4 mg/ml against SARS-CoV-2 and 0.004 to
0.06 mg/ml against SARS-CoV in the MLV
assay (Fig. 3E and fig. S9). Comparable neu-
tralization IC50s were observed in authentic
SARS-CoV and SARS-CoV-2 neutralization
assays (Fig. 3E and fig. S9). By contrast, the
VSV–SARS-CoV-2 neutralization IC50s were
substantially lower (8- to 35-fold) than those
observed for live SARS-CoV-2 (figs. S9 and
S10). To assess the breadth of neutralization
against representative preemergent SARS-like
bat CoVs, we measured infection inhibition
of authentic WIV1-CoV using a plaque reduc-
tion assay (16). All eight antibodies neutralized
WIV1-CoV, withmedian plaque reduction neu-
tralization titers (PRNT50s) ranging from 0.076
to 1.7 mg/ml, demonstrating their breadth of
activity (Fig. 3E and fig. S11). Crucially, none of
the antibodies left an unneutralized viral frac-
tion in any of the assays (figs. S9 and S11).
We observed little to no correlation between
apparent binding affinity for wild-type (WT)
SARS-CoV-2 cell surface S and neutralizing
activity. For example, all of the S2-directed
antibodies and a subset of NTD-directed anti-
bodies bound with high avidity to both re-
combinant and cell surface S, but none were
neutralizing (Fig. 3F). Surprisingly, evenwithin
the group of hACE2-blocking nAbs, we did not
observe a strong correlation between binding
to cell surface–S or recombinant-S and neu-
tralization, suggesting that antibody potency
is governed at least in part by factors beyond
binding affinity (Fig. 3F and figs. S12 and S13).
To determine whether the hACE2 competitor
antibodies neutralized by inducing S1 shedding
and premature S triggering (17), we incubated
human embryonic kidney (HEK)–293 cells ex-
pressing WT SARS-CoV-2 S with saturating
concentrations of antibody andmeasured the
median fluorescence intensity (MFI) of anti-
body binding over time by flow cytometry.
Indeed, all of the hACE2-blocking antibodies
showed substantially decreased binding over
time, consistent with induced S1 dissociation,
whereas antibodies recognizing the NTD, S2
stem, and RBD epitopes outside of the hACE2
binding site displayed either no change or an
increase in binding over time (Fig. 3G). We
conclude that SARS-CoV infection induces
high-affinity cross-reactive antibodies targeting
multiple distinct antigenic sites on the S pro-
tein, but neutralizing activity is primarily
restricted to RBD-directed antibodies that
interfere with receptor binding and promote
S1 dissociation.
To structurally characterize the epitopes
recognized by the RBD-directed nAbs, we
performed negative-stain electron microscopy
(EM) to observe each of these Fabs bound to
the SARS-CoV-2 S protein. Many of the two-
dimensional (2D) class averages that we ob-
tained displayed obvious heterogeneity in the
number of Fabs that were bound to a single
S trimer, which is likely due to dynamic in-
accessibility of RBD epitopes and substoi-
chiometric binding of S at the low protein
concentrations used to prepare grids (Fig. 4A)
(5, 18). The 3D reconstructions of these com-
plexes support the results of our biophysical
competition assays and show that the RBD-
directed nAbs recognize a single region on
the solvent-exposed surface of the RBD with
overlapping footprints. ADI-55689, which po-
tently neutralizes and competes with hACE2,
appears to bind at the edge of the hACE2
binding site, close to the more structurally
conserved core domain of the RBD, without
overlapping with the CR3022 epitope (Fig.
4B). ADI-56046, which exemplifies the group
of antibodies that compete with both hACE2
and CR3022, binds slightly farther away from
the flexible tip of the RBD, and thus its epitope
spans both the hACE2 binding site and the
CR3022 epitope (Fig. 4C). Our structural anal-
ysis suggests that all of the nAbs recognize a
single patch on the surface of the RBD with
overlapping footprints. These antibodies po-
tently cross-neutralize SARS-CoV, SARS-CoV-2,
and WIV1, suggesting that this antigenic sur-
face exhibits extensive conservation among
the SARS-like coronaviruses.
The potent cross-neutralizing antibodies de-
scribed here bind to conserved epitopes over-
lapping the hACE2 binding site, thus illuminating
this antigenic surface as a promising target for
the rational design of pan-sarbecovirus vac-
cines. For example, the RBD epitope(s) defined
by this class of antibodies could be presented
on conformationally stable protein scaffolds to
focus the antibody response on this site, as
previously demonstrated for themotavizumab
epitope on respiratory syncytial virus F (19).
Furthermore, the nAbs themselves, alone or in
combination, represent promising candidates
for prophylaxis or therapy of SARS, COVID-19,
and potentially future diseases caused by new
emerging SARS-like viruses.
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